東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

HIV-1 based viral vector development...

Huentelman, Matthew J.

FindBook

Google Book

Amazon

博客來

HIV-1 based viral vector development for gene transfer to the cardiovascular system.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	HIV-1 based viral vector development for gene transfer to the cardiovascular system./
作者:	Huentelman, Matthew J.
面頁冊數:	107 p.
附註:	Source: Dissertation Abstracts International, Volume: 65-03, Section: B, page: 1095.
Contained By:	Dissertation Abstracts International65-03B.
標題:	Biology, Animal Physiology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3127664
ISBN:	0496749285

HIV-1 based viral vector development for gene transfer to the cardiovascular system.
Huentelman, Matthew J.

HIV-1 based viral vector development for gene transfer to the cardiovascular system. - 107 p.

Source: Dissertation Abstracts International, Volume: 65-03, Section: B, page: 1095.

Thesis (Ph.D.)--University of Florida, 2003.

Cardiovascular disease (CVD) is the nation's number one killer. Several pharmacotherapies exist to combat CVD however its incidence and mortality rates continue to rise. Alternative treatment options must be explored in order to provide hope for the future treatment of this disease. Gene therapy has been suggested as one such alternative option.

ISBN: 0496749285Subjects--Topical Terms:

1017835
Biology, Animal Physiology.

HIV-1 based viral vector development for gene transfer to the cardiovascular system.
LDR:03264nmm 2200313 4500 001 1838962
005 20050526092516.5
008 130614s2003 eng d
020 $a 0496749285
035 $a (UnM)AAI3127664
035 $a AAI3127664
040 $a UnM $c UnM
100 1 $a Huentelman, Matthew J. $3 1927368
245 1 0 $a HIV-1 based viral vector development for gene transfer to the cardiovascular system.
300 $a 107 p.
500 $a Source: Dissertation Abstracts International, Volume: 65-03, Section: B, page: 1095.
500 $a Chair: Mohan K. Raizada.
502 $a Thesis (Ph.D.)--University of Florida, 2003.
520 $a Cardiovascular disease (CVD) is the nation's number one killer. Several pharmacotherapies exist to combat CVD however its incidence and mortality rates continue to rise. Alternative treatment options must be explored in order to provide hope for the future treatment of this disease. Gene therapy has been suggested as one such alternative option.
520 $a Gene therapy involves the transfer of therapeutic nucleic acid into diseased cell types. The vector for such gene transfer is of major consideration when approaching any disorder. Viral vectors based on HIV-1 are an up and coming class of gene transfer vehicles first utilized in 1996 and already finding their way into human clinical trials. However the HIV-1 vectors, or lentiviral vectors, are poorly characterized in almost every major organ of the CV system. Lentiviral vectors possess many of the characteristics required for effective gene therapy for CVD including the ability to accommodate large payloads of nucleic acid, transduce non-dividing cells, direct long-term transgene expression, and evoke a miniscule immune response. However, many challenges face lentiviral vectors including questions about their safety for use in humans and technical hurdles concerning their large-scale preparation. The primary goal of this study was to further develop the lentiviral vector system and characterize its efficacy in the CV system and its ability to prevent CVD.
520 $a Novel methods were developed for the production and concentration of the vector allowing for reproducible large-scale production. Upon delivery to neonatal rats, the lentiviral vector transduced every major target organ of the rat cardiovascular system including the heart, liver, brain, kidney, and adrenal gland. The optimal vector dose was determined, and additional studies using an angiotensin II type 2 receptor transgene illustrated the ability of the vector to prevent the development of hypertrophy in a spontaneous model of hypertension in the rat.
520 $a The methodology of lentiviral vector preparation was improved and its effectiveness in the CV system illustrated. Initial results using a therapeutic transgene show promise for the future study of cardiac hypertrophy. The findings here help to lay the foundation for future use of the lentiviral vector in the study and possible therapy of CVD.
590 $a School code: 0070.
650 4 $a Biology, Animal Physiology. $3 1017835
650 4 $a Biology, Molecular. $3 1017719
690 $a 0433
690 $a 0307
710 2 0 $a University of Florida. $3 718949
773 0 $t Dissertation Abstracts International $g 65-03B.
790 1 0 $a Raizada, Mohan K., $e advisor
790 $a 0070
791 $a Ph.D.
792 $a 2003
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3127664